A Phase 1 interventional study of SB17170 in Solid Tumor, sponsored by SPARK Biopharma. Recruiting at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by SPARK Biopharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
This is an open-label, multicenter, Phase 1 clinical trial to evaluate the maximum tolerated dose, safety, pharmacokinetic/pharmacodynamic characteristics and preliminary anti-tumor activity of SB17170 when administered alone(1a) and co-administered with standard of care(1b) to patients with locally advanced or metastatic solid tumors who have failed standard of care.
1 cycle of treatment of this clinical trial is 21 days, and tumors are assessed every 2 cycles.
SPARK Biopharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort
Drug: SB17170
SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort
Drug: SB17170
SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort
Drug: SB17170
SB17170 capsules, Oral administration 21days/cycle
Safety and tolerability of SB17170
Evaluate DLT to estimate the maximum tolerated dose (MTD), and determine a recommended Phase 2 dose (RP2D).
Time frame: At the end of Cycle 1 (each cycle is 21 days)
Pharmacokinetic(Cmax)
Peak Plasma Concentration
Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)
Pharmacokinetic(Tmax)
Time to Peak Plasma Concentration
Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)
Pharmacokinetic(AUC)
Area under the plasma concentration versus time curve
Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)
The anti-tumor activity with RECIST v1.1
CT/MRI every 6 weeks
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 100weeks
Pharmacodynamics(TIL)
Tumor infiltrated lymphocyte in Tumor tissue
Time frame: At Day1 and D22 of Cycle 1 (each cycle is 21 days)
Pharmacodynamics(TAM)
Tumor Associated Macrophage at Tumor Tissue
Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)
Pharmacodynamics(T cell activation)
T cell activation in Blood
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)
Pharmacodynamics(PD-L1)
PD-L1 in Blood and D1 of each cycle
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)
Pharmacodynamics(High Mobility Group Box 1 )
HMGB1 in Blood and Tissue
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)
Pharmacodynamics(S100A8)
S100A8 in Blood
Time frame: At Day1 and D21 of Cycle 1 t and D1 of each cycle (each cycle is 21 days)
Pharmacodynamics(S100A9)
S100A9 in Blood
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)
Pharmacodynamics(CXCL8)
CXCL8 in Blood
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)
Pharmacodynamics(MDSC)
Rate of Myeloid-Drived Suppressor Cell in Blood
Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HMGB1 Inhibitor SB17170